Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Camrellizumab combined with stereotactic radiotherapy, apatinib mesylate and albumin-conjugated paclitaxel for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer with non-sensitive gene mutations: a prospective, single arm, single center, exploratory clinical study

Next Previous
Trial Profile

Camrellizumab combined with stereotactic radiotherapy, apatinib mesylate and albumin-conjugated paclitaxel for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer with non-sensitive gene mutations: a prospective, single arm, single center, exploratory clinical study

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Feb 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Camrelizumab (Primary) ; Paclitaxel (Primary) ; Rivoceranib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use

Most Recent Events

  • 04 Feb 2020 Study phase is given as 0, the trial focus is TU and the patients no is 40, drug is treating the disease, hence I have assumed phase 2nd. Line of therapy added as per the official title. Route and form assumed from the RDI and I have tagged all the drug primary as combination in focus. Kindly update further.
  • 04 Feb 2020 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top